ReviewCell & bioscience2025
Pluripotent stem cells-based neural organoids for modelling human brain development and diseases.
Review in Cell & bioscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Dasatinib Cube-O-Needle hybrid system for effective and safe site-specific treatment for triple-negative breast cancer.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Brain organoids have emerged as transformative in vitro models for studying human neurodevelopment, neural disorders, and evolutionary brain complexity. This review systematically compares neural development in mice and humans, reflecting the limitations of traditional rodent models and highlights the importance of organoid technology. It synthesizes evolutionary, cellular, and molecular perspectives through comprehensive analysis of literature, detailing the evolution of brain organoid technologies, from early "unguided" whole-brain models to region-specific, vascularized, and assembloid systems that recapitulate inter-regional connectivity. The integration of multi-omics approaches including transcriptomics, epigenomics, and proteomics with organoids has enabled rigorous validation of their fidelity to in vivo development and uncovered novel disease mechanisms. We further explore applications of organoids in modeling cellular dynamics, elucidating gene functions, and replicating neurodevelopmental disorders such as autism, microcephaly, and Rett syndrome. Finally, we discuss their utility in high-throughput drug screening and personalized medicine, while addressing ongoing challenges including vascularization, functional maturation, and ethical considerations. Critically, these advances in organoid technology bridge translational gaps by enabling patient-specific disease modeling, accelerating therapeutic discovery, and providing human-relevant platforms to overcome precision neuroscience. By leveraging mouse and human brain organoids to transcend species limitations in neural research, this review offers unprecedented insights into brain development and pathology.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.